drugset / Trial / NCT03470337

Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance

NCT03470337 ↗

Phase 3 Completed 100 enrolled Mucos Pharma GmbH & Co. KG
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

Oral enzyme therapy in patients with acute superficial vein inflammation (thrombophlebitis) can serve as an additional treatment option besides standard therapy with compression stockings, common pain medication and physical treatments. This randomized, double-blinded trial compares efficacy and safety with placebo.

Timeline

Start
1996-09
Primary completion
1997-06
Completion
1997-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Phlogenzym Unknown 6 unknown Oral

Indications